Miae Kim, PharmD, MS, BCPS, received a master’s degree in Clinical Pharmacy from Seoul National University in South Korea, then moved to the U.S. where she graduated Summa Cum Laude with high distinction from the University of Minnesota with a PharmD. She completed her PGY-1 pharmacy practice training at Beth Israel Deaconess Medical Center, and did a PGY-2 training in solid organ transplant at Brigham and Women?s Hospital in Boston. Dr. Kim joined the Center for Advanced Heart Disease at Brigham and Women’s Hospital as a heart transplant/MCS pharmacy specialist in 2013, working in both the inpatient and outpatient settings. She attained board certification as a Pharmacotherapy Specialist in 2013. Dr. Kim’s current interests include cardiac transplant complications, antibody-mediated rejection, and cardiac allograft vasculopathy, and she has published in multiple peer-reviewed journals and textbooks and presented at local, national, and international transplant conferences.

Carrie Hyde, MD is a dynamic medical professional known for their expertise in pain management, opioid prescribing, and holistic patient care. With a background in internal medicine, specialized training in palliative care, and formal education in acupuncture, Dr. Hyde offers a unique blend of traditional and integrative medicine.

As the West Regional Medical Director and national supportive care director at Monogram Health, Dr. Hyde plays a pivotal role in optimizing patient care on a larger scale. They are a compassionate advocate for individuals dealing with complex health challenges and continues to see patients in her local community.

Melissa J. Durham is an Associate Professor of Clinical Pharmacy and an Associate Dean at the University of Southern California (USC) Mann School of Pharmacy and Pharmaceutical Sciences.  Dr. Durham received her Doctor of Pharmacy degree, completed a residency in Community-based Pharmacy Practice, and has a Master of Academic Medicine degree, all from USC. She has been a clinical pharmacist at the USC Pain Center since 2008, where she runs a pharmacist-led pain medication management service for patients with a variety of complicated chronic, nononcologic pain conditions. She is dedicated to improving the quality of life for people with chronic pain through patient-centered and compassionate care. The value of her unique practice model has been recognized and published both nationally and internationally. Dr. Durham is also a practicing community pharmacist and provides a valuable and unique perspective of a clinician who is both a prescriber and a dispenser.

Johnathan Goree, MD, is a Professor of Anesthesiology at the University of Arkansas for Medical Sciences (UAMS), where he is the Director of the Chronic Pain Division, Program Director of the Pain Medicine Fellowship, and Chair of the Opioid Stewardship Committee. Dr. Goree completed medical school and residency at the Weill College of Medicine at Cornell University. He completed a Pain Fellowship at Emory University in Atlanta prior to joining the faculty at UAMS. Dr. Goree considers himself a quality-of-life physician who is focused on improving function through opioid-sparing interventional care. His research interests include the effects of opioid education, racial disparities in chronic pain care, and implementation science.

Neal J. Weinreb, MD, FACP is a graduate of the Jewish Theological Seminary (Bachelor of Hebrew Literature), and SUNY Downstate Health Sciences University (MD, summa cum laude). After a residency in Internal Medicine at Albert Einstein College of Medicine and a fellowship and faculty position at Mt. Sinai School of Medicine, NY, he practiced Hematology and Medical Oncology in South Florida. Dr. Weinreb, the director of the University Research Foundation for Lysosomal Storage Diseases in Boca Raton, FL, retired from clinical practice in May 2018. He now devotes his entire professional attention to clinical research about Gaucher Disease and Fabry Disease. Dr Weinreb is a Voluntary Associate Professor of Human Genetics and Medicine at the University of Miami Miller School of Medicine. Dr. Weinreb is an investigator for the Gaucher and Fabry Registries and a member of the Medical Advisory Board for the National Gaucher Foundation and of the International Working Group for Gaucher Disease.

Dr. Coy Heldermon is an associate professor of medicine and board-certified medical oncologist at the University of Florida with expertise in the treatment of breast cancer. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases.

Dr. Roshan Lal is a Pediatric Clinical and Metabolic Geneticist working at the Rare Disease Institute, Children’s National Hospital in Washington DC. Her clinical and research interests are geared towards improving the quality of life for children with rare genetic diseases, specifically lysosomal storage diseases and neuro-genetic disorders. Her special interest includes being involved in clinical trials using orphan drugs as well as gene therapy. She is currently the Director of Clinical Trials and Director of International Patient Consultations and Care Referrals for the Rare Disease Institute at the Children’s Hospital.

Dr. Angela Fleischman is a physician-scientist investigating hematologic malignancies. She integrates her research with the clinical care of patients with these diseases.

Her laboratory focuses on the role of inflammation in MPN. Her overarching research goal is to identify what drives disease initiation in MPN and to ultimately translate her scientific discoveries into therapeutic benefit for MPN patients.

Her research program spans the entire translational research spectrum. In the lab, she studies the fundamental pathobiology of MPN through mouse modeling and in vitro experimentation with primary patient samples. Her clinical work informs her research, and accordingly Dr. Fleischman’s research methods primarily involve patient samples for in vitro assays of stem and progenitor function.

Aaron Gerds, MD, MS, completed his undergraduate degree, a BA in biology and chemistry, with honors at Hope College in Holland, Michigan and obtained his MD from Loyola University Chicago Stritch School of Medicine. He continued his Internal Medicine residency at Loyola University Hospital where he served as chief resident. In Chicago, he became interested in hematology clinical trials which led him to pursue a master’s degree in clinical research methods and epidemiology. Dr. Gerds completed his hematology and oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center, in Seattle and pursued a subspecialty in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as other myeloid disorders. During his fellowship, he was awarded the ASBMT’s New Investigator Award.

Dr. Gerds is an Associate Professor of Medicine and the Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute where he serves as the principal investigator for several clinical trials for the treatment of MPNs and myeloid neoplasia with a focus on developing new treatments for these patients. He is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving as Chair of the Committee on Communications, as a member of the Test Materials Development Committee, former Editor of the ASH News Daily, and current Editor-in-Chief of ASH Clinical News. Dr. Gerds serves as the Medical Director for the Case Comprehensive Cancer Center’s Clinical Research Office and is co-PI for the Center’s LAPS grant. He is also the institutional PI for the SWOG Cancer Research Network and is part of the leadership on several national clinical trials and is the chair of the National Comprehensive Cancer Network (NCCN) Myeloproliferative Neoplasms and Systemic Mastocytosis Guidelines.

Dr. Mesa was the inaugural panel chair of the National Comprehensive Cancer Network’s (NCCN) guideline panel for the first USA guidelines for MPNS (myelofibrosis, polycythemia vera and essential thrombocythemia). He has been the principal investigator or co-principal investigator of more than 100 cancer clinical trials, including numerous global phase III trials. He has over 800 lifetime medical publications, with more than 400 peer-reviewed manuscripts, 15 book chapters, and two edited books. He is a frequently invited speaker on MPNs with over 600 such lectures and visiting professorships, nationally and internationally.

Dr. Mesa is a funded investigator of the National Cancer Institute (NCI) on several projects in myeloproliferative neoplasms and has been appointed to the NCI Clinical Trial Advisory Committee. He plays a range of leadership roles with the American Society of Hematology (ASH), the American Association of Cancer Research (AACR), and is currently elected to the Board of the American Association of Cancer Institutes (AACI), and Leukemia and Lymphoma Society.

In addition to Dr. Mesa’s extensive MPN research and clinical practice, he is passionate about advancing cancer health equity and increasing minority patients’ participation in cancer clinical trials. He helped implement a mandate that each new trial at the Mays Cancer Center has a Minority Accrual Plan that includes enrollment projections and a demographic-specific toolbox with strategies for clinical investigators to promote enrollment. Before its implementation, the enrollment of Hispanics into the cancer center’s interventional studies was 46 percent; now, it is 56 percent. He is involved in numerous national initiatives to increase clinical trial diversity, including being a member of the Genentech Health Disparities Task Force, Bristol Myers Squibb Health Disparities Task Force and the Janssen Health Disparities Task Force. In March 2022, he testified on the importance of clinical trial diversity before the House Committee on Energy and Commerce. Dr. Mesa also co-led the Mays Cancer Center’s biennial Advancing the Science of Cancer in Latinos Conference held in San Antonio.

Dr. Duong is the director of clinical outcomes research and development at Stanford University Neuromuscular division. Clinically, she is a physical therapist with 20 years of clinical experience in evaluating, treating, and validating clinical outcomes for patients with neuromuscular disease. She is involved in ongoing studies and developments on initiatives in treatments for neuromuscular disease, novel trial designs, and outcomes development. Prior to her arrival at Stanford University in 2015, she directed clinical evaluations and training for an international network, Cooperative International Neuromuscular Research Group (CINRG), in Washington, DC.

Her clinical and research interests in developing, refining, and understanding outcome measures in neuromuscular disease contributes to her determination in improving efficacy endpoints for clinical trials as well as interpreting these endpoints on the changing phenotype in neuromuscular diseases. Her area of research focuses on the impact of exercise and physical activity on disease physiology and quality of life. She hopes to integrate technology and digital biomarkers as a complementary tool to performance-based measures used in trials, in the clinic, and remotely.

She enjoys working on multi-disciplinary teams, mentorship, and creating patient-focused solutions to improve the quality of life for all neuromuscular patients. Her interests and hobbies include hiking, running, gardening, and working with technology and design products to make the world more accessible for individuals with different abilities.

Vanessa Battista, DNP, MBA, MS, RN, CPNP-PC, CHPPN, FPCN is a board-certified Pediatric Nurse Practitioner (PNP) and currently serves as Senior Nurse Director of Palliative Care at the Dana Farber Cancer Institute. Previously, she practiced as a PNP on the Pediatric Advanced Care Team (PACT) at the Children’s Hospital of Philadelphia (CHOP). She also served at the neuromuscular centers at CHOP, the Columbia University Medical Center, and the Children’s Hospital of Boston. Dr. Battista was clinical faculty at the Boston College Connell School of Nursing where she developed the Pediatric Palliative Care Masters subspecialty program.

Dr. Battista also serves as a board member and consultant for various organizations that provide services for patients and families living with life-threatening diseases. She lectures and teaches at the local, national, and international level, and is a member of the End-of-Life Nursing Education Consortium (ELNEC) pediatric faculty. Dr. Battista is an active reviewer for publications and grants, and has authored several book chapters and articles on various aspects of pediatric palliative care and neuromuscular disease.

Dr. Battista was a Jonas Nursing Scholar, and the recipient of the ELNEC Award for Excellence, the Distinguished Young Alumni Award from Columbia University, and the DNP Leadership Award from Johns Hopkins University. She also earned Clinical Master status among advanced practice providers at CHOP. She earned her bachelor’s degree from Boston College in psychology, with minors in health sciences and faith, peace, and justice studies; her nursing degree and master’s degree from Columbia University School of Nursing; and completed a certificate in Pastoral Ministry at the Boston College School of Theology and Ministry. Dr. Battista obtained her Master of Business Administration and Doctor of Nursing Practice from Johns Hopkins University.

Dr. Chiriboga is Professor of Neurology and Pediatrics at Columbia University Irving Medical Center (CUIMC) and former Interim Director of the Division of Child Neurology, Departments of Neurology and Pediatrics, Vagelos College of Physicians and Surgeons. She is also former Chief of Pediatric Neurology at Columbia University’s affiliate hospital, Harlem Hospital Center.

Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. Dr. Chiriboga completed training in pediatrics at St. Luke’s-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies’ Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Child Neurology at NewYork-Presbyterian/Columbia University Irving Medical Center. Subsequently, she completed a Neuroepidemiology fellowship at the Gertrude H. Sergievsky Center and received a master’s in public health from the Mailman School of Public Health, Columbia University. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and the American Board of Psychiatry and Neurology (ABPN). She is a diplomate of the ABPN in Child Neurology.

Dr. Chiriboga’s current research focuses on Spinal Muscular Atrophy (SMA) clinical trials. Past areas of research, including NIH funding, have focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on neuromuscular disorders as well as developmental, neurobehavioral neurology, and migraine, and on the treatment of spasticity.

Yolanda Mageto, MD, MPH, ATSF, a pulmonary critical care specialist with nationally recognized expertise in interstitial lung disease (ILD), has assumed the role of Medical Director of Interstitial Lung Disease at Baylor University Medical Center at Dallas in Dallas, Texas. Dr. Mageto attended medical school at Washington University in St. Louis, Missouri, and completed her residency and training at University of Texas Southwestern and fellowship in pulmonary and critical care medicine at the University of Washington in Seattle with a focus in ILD. Since that time, she has held faculty positions at the University of Washington Seattle, University of Texas Southwestern, and, most recently, University of Vermont, where she rose to the rank of full professor. Dr. Mageto is a clinician, educator, and researcher involved in multiple idiopathic pulmonary fibrosis/ILD trials over last 20 years including collaborations with investigators from other centers in sarcoidosis-related lung disease. She remains actively involved in the total care and management of her patients. Dr. Mageto is dedicated to the development of a Comprehensive Integrated Interstitial Lung disease program, optimizing delivery of care to patients with ILD in the Dallas Fort Worth Area. In her spare time, she enjoys spending time with her family, travelling, reading a good book, and cooking.

Fernando J. Martinez, MD, MS, is chief of the Division of Pulmonary and Critical Care Medicine at NewYork-Presbyterian Hospital and Weill Cornell Medicine in New York City. He received his medical degree from the University of Florida in Gainesville, Florida, and completed his internal medicine residency at Beth Israel Hospital/Harvard Medical School and fellowship in pulmonary and critical care medicine at Boston University in Boston, Massachusetts. Additionally, Dr. Martinez received a master’s degree in biostatistics and clinical study design from the University of Michigan School of Public Health in Ann Arbor, Michigan.

A premiere translational researcher in chronic lung disease, Dr. Martinez is nationally and internationally recognized for his seminal studies in phenotypic and functional classification, and clinical interventions in chronic obstructive pulmonary disease and interstitial lung disease. He has authored 282 peer-reviewed manuscripts, 32 review articles, and 32 book chapters. Dr. Martinez is a member of the American College of Chest Physicians, the American Thoracic Society, and the American Association of Cardiovascular and Pulmonary Rehabilitation.

Dr. Ayodeji Adegunsoye is a pulmonary and critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.

Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, health care disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. Dr. Adegunsoye’s work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of his research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.

Currently, the main focus of Dr. Adegunsoye’s work is utilizing genetic data from a diverse patient population to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.